Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany Joins Decision To Suspend AZ Vaccine Over Safety, But Is It Really The Most ‘Cautious’ Approach?

Countries At Odds With EMA Guidance

Executive Summary

AstraZeneca’s vaccine is under suspicion again, this time over safety, rather than efficacy, and the European Medicines Agency has promised a swift review.

You may also be interested in...



AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors

Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.

Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails

The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel